Edition:
India

Kyowa Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,721JPY
14 Aug 2020
Change (% chg)

¥7 (+0.26%)
Prev Close
¥2,714
Open
¥2,710
Day's High
¥2,735
Day's Low
¥2,690
Volume
1,260,500
Avg. Vol
978,718
52-wk High
¥3,025
52-wk Low
¥1,746

Select another date:

Thu, Jul 9 2020

BRIEF-Mylan And Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval Of Hulio (Adalimumab-Fkjp)

* MYLAN AND FUJIFILM KYOWA KIRIN BIOLOGICS ANNOUNCE U.S. FDA APPROVAL OF HULIO® (ADALIMUMAB-FKJP)

BRIEF-Ultragenyx And Kyowa Kirin Announce U.S. FDA Approval Of Crysvita(Reg) (Burosumab) For The Treatment Of Tumor-Induced Osteomalacia (TIO)

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE U.S. FDA APPROVAL OF CRYSVITA(REG) (BUROSUMAB) FOR THE TREATMENT OF TUMOR-INDUCED OSTEOMALACIA (TIO) Source text - https://bit.ly/2UXTP2H Further company coverage:

BRIEF-Kyowa Kirin Says Presented Impact Of Baseline Dyskinesia On Safety And Efficacy Of Nourianz In Patients With Parkinson's Disease

* KYOWA KIRIN CO LTD - IMPACT OF BASELINE DYSKINESIA ON SAFETY AND EFFICACY OF NOURIANZ IN PATIENTS WITH PARKINSON'S DISEASE PRESENTED

BRIEF-Mei Pharma And Kyowa Kirin Announce Updated Clinical Data From Early-Stage Follicular Lymphoma Study

* MEI PHARMA AND KYOWA KIRIN ANNOUNCE UPDATED CLINICAL DATA FROM THE PHASE 1B STUDY EVALUATING ME-401 ON AN INTERMITTENT SCHEDULE IN PATIENTS WITH FOLLICULAR LYMPHOMA AND OTHER B-CELL MALIGNANCIES; DATA TO BE FEATURED IN THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Mei Pharma And Kyowa Kirin Announce Global License, Development And Commercialization Agreement For Me-401

* MEI PHARMA AND KYOWA KIRIN ANNOUNCE GLOBAL LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR ME-401

BRIEF-Ultragenyx And Kyowa Kirin Announce FDA Acceptance And Priority Review Designation Of Supplemental Biologics License Application For Crysvita

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR CRYSVITA® (BUROSUMAB) FOR TUMOR-INDUCED OSTEOMALACIA (TIO)

Select another date: